TITLE
Bryan Bell : Towards integrating immunotherapy into the treatment of locally advanced HNSCC
TALK INFO
Dr. Bell is in developing new approaches to improve the outcome of surgery for the treatment of head and neck cancer. His work has been published in more than 150 scientific articles. He is co-author of two major textbooks, including "Oral, Head and Neck Oncology and Reconstructive Surgery".
THIS EVENT IS ACCREDITED
CLINICAL PATHWAY
Pathology
SPEAKER
DATE
06/05/24
LEARNING OBJECTIVES
By the end of this session, participants will be able to:
Understand the biological rationale and mechanisms of action of immunotherapy in head and neck squamous cell carcinoma (HNSCC).
Review current evidence and clinical trial data supporting the use of immunotherapy in locally advanced HNSCC.
Identify potential roles for immunotherapy in neoadjuvant, concurrent, and adjuvant treatment settings.
Recognize patient selection factors and biomarkers relevant to immunotherapy response in HNSCC.
Discuss challenges, limitations, and toxicities associated with integrating immunotherapy into multimodal treatment strategies.
Evaluate future directions and ongoing research shaping the evolving role of immunotherapy in locally advanced HNSCC.
ABOUT THE SPEAKER
Dr. Bryan Bell, MD DDS FACS FRCS(Ed) is globally known head and neck cancer surgeon and researcher. His work has been published in more than 150 scientific articles and book chapters. In addition, he is co-author of two major textbooks, including "Oral, Head and Neck Oncology and Reconstructive Surgery".
His clinical practice is focused on the comprehensive surgical management of patients with head and neck cancer, including tumors of the oral cavity, oropharynx, larynx, thyroid and skull base. Along with his clinical practice, Dr. Bell currently holds a number of leadership positions. He is the Physician Executive and Director, Division of Surgical Oncology, Radiation Oncology, and Clinical Programs for Providence Cancer Institute Oregon. In addition, Dr. Bell is the Medical Director of the Providence Head and Neck Cancer Program, and Member and Director of Surgical Oncology Research at the Earle A. Chiles Research Institute in the Robert W. Franz Cancer Center, a division of the Providence Cancer Institute. Dr. Bell provides vision, leadership, strategy and oversight for all clinical oncology programs and surgical oncology research throughout the Oregon region.
CE ACCREDITATION
surgeOn is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry. surgeOn designates this activity for 1 credit hour of continuing education credits.
This event may also be accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 1 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. If you are a learner based in the U.S. or Canada EACCME credits are recognized by the American Medical Association (AMA) and the Royal College of Physicians and Surgeons of Canada.
DECLARATION
In accordance with criterion 13 of document UEMS 2023.07.rev “EACCME® Criteria for the Accreditation of Live Educational Events (LEEs)” and the Standard v. Commercial or Promotional Conflict of Interest, published by the American Dental Association Continuing Education Recognition Program (ADA CERP), all surgeON presenters sign a Conflict of Interest form to document all perceived or actual conflicts of interest for the last 3 years, whether due to a financial or other relationship. This document can be viewed at the beginning of the event or on request by emailing info@surgeon-events.org No fee, honorarium or arrangement for re-imbursement of expenses in relation to the this event has been provided to the speaker.
